Terpinen-4-ol

Phase 1Small molecule

BBioTissue Holdings, Inc

Terpinen-4-ol is one of 21 small molecule programs targeting Blepharitis. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

BlepharitisActive, not recruiting

BlepharitisPhase 1

Active, not recruiting

Competition

Competitive Landscape

39 competitors in Blepharitis

#DrugCompanyPhaseTrials

E-Mycin

AAzurity Pharmaceuticals

Approved

1 2

Stromectol

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Approved

—3

Elidel

BBausch Health Americas, Inc.

Levaquin

Tobrex

VViatris Specialty LLC

Flagyl

Lotemax

1 8

Decadron

AAspen Global Incorporated

Phase 3

1 9

Flovent

GSK

Phase 2

1 10

Azasite

Merck & Co.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Blepharitis1 trial

Demodex Blepharitis Treatment Study

Completed·BBioTissue Holdings, Inc·Phase 1·NCT01647217·17 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Terpinen-4-ol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Terpinen-4-ol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Terpinen-4-ol. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — BioTissue Holdings, Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: BBioTissue Holdings, Inc

Terpinen-4-ol

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Blepharitis1 trial

References

Drug Info

Quick Facts

Related News